Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Weaves Worldwide Web Of Partnerships In Quest For Innovative Drugs, CEO Says

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Facing the imminent expiration of American patents on some of its leading drugs, Takeda is building a matrix of partnerships and licensing arrangements in the quest to strengthen its sales of innovative products, according to CEO Yasuchika Hasegawa
Advertisement

Related Content

Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
U.S. FDA Offers Up Revised PDUFA Date In June For Takeda’s Alogliptin
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Takeda’s Febuxostat Gets U.S. FDA Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
Fresh Concerns Over Biosimilar ESA Use In Thailand Raises Takeda’s Hematide Prospects
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III
Advertisement
UsernamePublicRestriction

Register

SC069933

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel